AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-10. (Canceled)

11. (Previously Presented) A mutant *ras* peptide consisting of:

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:14);

wherein Xaa_1 is the amino acid lysine or tyrosine;

wherein Xaa_2 is an amino acid;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;

wherein when Xaa_2 is valine, Xaa_1 is tyrosine

and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

12. (Currently Amended) A mutant *ras* peptide which is a fragment of:

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:14);

wherein Xaa_1 is the amino acid lysine or tyrosine;

wherein Xaa_2 is an amino acid;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;

wherein when Xaa_2 is valine, Xaa_1 is tyrosine;

wherein said peptide includes Xaa_1 and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response ~~and wherein said fragment consists of 10 amino acids~~.

13. (Currently Amended) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:14);

wherein Xaa_1 is the amino acid tyrosine;

wherein Xaa_2 is valine;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine. cysteine, alanine, arginine. and serine;

wherein said peptide includes Xaa_1 and said peptide elicits a peptide-specific human CD8+ cytotoxic T lymphocyte immune response.

14. (Currently Amended) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:14);

wherein Xaa_1 is the amino acid lysine or tyrosine[[:]];

wherein Xaa_2 is selected from the group consisting of valine, tryptophan. leucine, tyrosine, and phenylalanine;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;

wherein when Xaa_2 is valine, Xaa_1 is tyrosine;

wherein said peptide includes Xaa_1 and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

15. (Previously Presented) A mutant *ras* peptide consisting of between 13 and 8 amino acids, wherein said peptide is the following peptide or a fragment thereof:

Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:14);

wherein Xaa_1 is tyrosine;

wherein Xaa_2 is an amino acid;

wherein Xaa_3 aspartic acid;

and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

16.-24. (Cancelled).

25. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

26. (Cancelled).

27. (Previously Presented) An immunogen for eliciting a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim 72, wherein the immunogen elicits a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

28.-31. (Cancelled).

32. (Previously Presented) A pharmaceutical composition comprising the mutant *ras* peptide of claim 72 and a pharmaceutically acceptable carrier.

33. (Previously Presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

34. (Previously presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

35.-65. (Cancelled).

66. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val

(SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, and poly-L-lysine.

67. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is tetanus toxoid.

68. (Previously Presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

69. (Cancelled).

70. (Previously Presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF, β2-microglobulin, or combinations thereof.

71. (Previously Presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

72. (Previously Presented) A mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:11).